Wegovy was recently approved by the FDA to treat weight loss for individuals with a BMI of 30 or higher (considered the obese category) and individuals with an overweight BMI (25 - 30) who also have a weight-related comorbidity (high blood pressure, high cholesterol, fatty liver disease, etc.)
Therapeutic dose phase (1.7 mg to 2.4 mg, weeks 17+) At full therapeutic doses, appetite suppression is at maximum
Key Development : In Dec 2025, Novo Nordisk announced that the FDA approved the Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term, and to reduce the risk of major adverse cardiovascular events the first oral GLP-1 receptor agonist therapy approved for weight management
Yes, but consistency is most important for side-effect tolerance and steady weight loss
Both tirzepatide and semaglutide are used for weight loss
May your side effects stay mild, your dose escalation stay smooth, and your protocols stay effective.
